Brokers Offer Predictions for Replimune Group Q3 Earnings

Replimune Group, Inc. (NASDAQ:REPL) – Equities researchers at Leerink Partnrs decreased their Q3 2025 earnings per share (EPS) estimates for Replimune Group in a report released on Tuesday, November 12th. Leerink Partnrs analyst J. Chang now anticipates that the company will earn ($0.71) per share for the quarter, down from their previous estimate of ($0.64). The consensus estimate for Replimune Group’s current full-year earnings is ($3.05) per share. Leerink Partnrs also issued estimates for Replimune Group’s Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.82) EPS and FY2026 earnings at ($2.25) EPS.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.07.

Other analysts have also recently issued reports about the company. Roth Mkm assumed coverage on Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 price objective for the company. JPMorgan Chase & Co. boosted their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. HC Wainwright restated a “buy” rating and set a $17.00 price objective on shares of Replimune Group in a research report on Tuesday, November 12th. Finally, Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $16.80.

Replimune Group Price Performance

Shares of REPL opened at $10.80 on Friday. The company has a market capitalization of $738.94 million, a price-to-earnings ratio of -3.54 and a beta of 1.19. Replimune Group has a fifty-two week low of $4.92 and a fifty-two week high of $12.97. The firm has a 50-day simple moving average of $11.46 and a 200-day simple moving average of $9.57. The company has a debt-to-equity ratio of 0.18, a quick ratio of 13.46 and a current ratio of 10.11.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Nisa Investment Advisors LLC lifted its holdings in Replimune Group by 10,304.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after acquiring an additional 4,946 shares during the period. Point72 DIFC Ltd acquired a new position in shares of Replimune Group during the 2nd quarter worth $57,000. Arizona State Retirement System purchased a new position in shares of Replimune Group in the 2nd quarter valued at about $108,000. Quest Partners LLC lifted its stake in shares of Replimune Group by 30.4% in the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after purchasing an additional 3,150 shares during the period. Finally, Erste Asset Management GmbH purchased a new stake in Replimune Group during the third quarter worth about $133,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.